, GlobeNewswire
Disclosure of shareholdings in accordance with articles 20 and 21 SESTA
Santhera Pharmaceuticals Holding AG /
Disclosure of shareholdings in accordance with articles 20 and 21 SESTA
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Disclosure of shareholdings in accordance with articles 20 and 21 SESTA
Liestal, Switzerland, August 23, 2011 - Santhera Pharmaceuticals (SWX: SANN) was
informed by Baker Bros. Advisors, LLC, 667 Madison Avenue, New York, NY 10065,
USA, that
- Baker Brothers Life Sciences, L.P.
- Baker Bros. Advisors, LLC
hold a total of 190'792 registered shares of Santhera Pharmaceuticals Holding
AG, representing 5.21% of the voting rights of the shares registered in the
Commercial Register. Baker Bros. Advisors, LLC is the investment manager of
Baker Brothers Life Sciences, L.P. Contact person at Baker Bros. Advisors, LLC
is Leo Kirby (phone/fax: +1 212 339 5633/ +1 212 339 5688).
Baker Bros. Advisors, LLC is a privately owned investment manager primarily
investing in healthcare stocks across micro- to mid-market capitalizations. The
firm is a growth investor seeking companies with innovative products that have
undervalued, mispriced current share prices. Baker Bros. Advisors was founded in
2000 and is based in New York, NY, USA.
* * *
For further information, contact
Thomas Staffelbach, Head Public & Investor Relations
Phone +41 (0)61 906 89 47
thomas.staffelbach@santhera.com
--- Ende der Mitteilung ---
Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Schweiz
ISIN: CH0027148649;
Baker:
http://hugin.info/137261/R/1540274/470908.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1540274]
Disclosure of shareholdings in accordance with articles 20 and 21 SESTA
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Disclosure of shareholdings in accordance with articles 20 and 21 SESTA
Liestal, Switzerland, August 23, 2011 - Santhera Pharmaceuticals (SWX: SANN) was
informed by Baker Bros. Advisors, LLC, 667 Madison Avenue, New York, NY 10065,
USA, that
- Baker Brothers Life Sciences, L.P.
- Baker Bros. Advisors, LLC
hold a total of 190'792 registered shares of Santhera Pharmaceuticals Holding
AG, representing 5.21% of the voting rights of the shares registered in the
Commercial Register. Baker Bros. Advisors, LLC is the investment manager of
Baker Brothers Life Sciences, L.P. Contact person at Baker Bros. Advisors, LLC
is Leo Kirby (phone/fax: +1 212 339 5633/ +1 212 339 5688).
Baker Bros. Advisors, LLC is a privately owned investment manager primarily
investing in healthcare stocks across micro- to mid-market capitalizations. The
firm is a growth investor seeking companies with innovative products that have
undervalued, mispriced current share prices. Baker Bros. Advisors was founded in
2000 and is based in New York, NY, USA.
* * *
For further information, contact
Thomas Staffelbach, Head Public & Investor Relations
Phone +41 (0)61 906 89 47
thomas.staffelbach@santhera.com
--- Ende der Mitteilung ---
Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Schweiz
ISIN: CH0027148649;
Baker:
http://hugin.info/137261/R/1540274/470908.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1540274]
Relevante Links: Santhera Pharmaceuticals Holding AG